In this issue:
Switching from reference adalimumab to biosimilar SB5
Switching efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference
Percutaneous vertebroplasty in acute osteoporotic vertebral compression fractures
Long-term efficacy & safety with belimumab in SLE
Infliximab biosimilar: tangible cost savings in Korea
Adalimumab generates substantial economic benefits
No adverse pregnancy outcomes with biologics use
99Tc-MDP appears to benefit refractory AS
Offer rituximab early in severe or refractory GPA
EULAR advice on pain management for inflammatory arthritis & OA
Please login below to download this issue (PDF)